Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation

Sorafenib, the first‐line agent for treatment of advanced hepatocellular carcinoma (HCC), improves median overall survival by approximately 3 months. In the present study, we investigated whether sorafenib combined with cucurbitacin B (CuB), a natural tetracyclic triterpenoid isolated from Cucurbita...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoli, Li, Hua, Li, Dong, Bai, Yudi, Zhang, Yao, Yan, Xue, Li, Jin, Zhao, Ri, Liu, Jiahui, Liu, Wei, Shi, Maolin, Xu, Cheng, Yang, Tai, Zhang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780105/
https://www.ncbi.nlm.nih.gov/pubmed/33176070
http://dx.doi.org/10.1002/2211-5463.13035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780105/
https://www.ncbi.nlm.nih.gov/pubmed/33176070
http://dx.doi.org/10.1002/2211-5463.13035

Ejemplares similares